Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Bupivacaine vs Peripheral Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18 years of age or older~2. Patients undergoing elective primary ankle or hindfoot surgery (ankle arthrodesis, subtalar arthrodesis, triple arthrodesis, total ankle arthroplasty, peroneal tendon debridement/transfer, Cavus Reconstruction, Medial Displacement Calcaneal Osteotomy, Dwyer Osteotomy)~Exclusion Criteria:~1. Patients who are undergoing revision surgical procedure~2. Patients who have taken opioid pain medications in the past 3 months prior to surgical procedure~3. Patients who have allergies to any of the medications or components of medications investigated in the study~4. Patients currently incarcerated~5. Patients who cannot read and speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Bupivacaine Group (Type: EXPERIMENTAL): No peripheral nerve block will be given. Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area.
- Peripheral Nerve Block Group (Type: ACTIVE_COMPARATOR): Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block). No local analgesic agent infiltration

Based on this trial design, predict the completion outcome and termination type (if applicable).